Operator
Good morning, ladies and gentlemen, and welcome to the Cooper-Standard First Quarter 2021 Earnings Conference Call. [Operator Instructions]
I would now like to turn the call over to Roger Hendriksen, Director of Investor Relations.
Roger Hendriksen
Director, Investor Relations
Thanks, Melanie, and good morning everyone. We really appreciate you taking the time to join our call this morning. The members of our leadership team, who will be speaking with you on the call this morning are Jeff Edwards, Chairman and Chief Executive Officer; and Jon Banas, Executive Vice President and Chief Financial Officer.
Before we begin, I need to remind you that this presentation contains forward-looking statements. While these statements are made based on current factual information and certain assumptions and plans that management currently believes to be reasonable, these statements do involve risks and uncertainties. For more information on forward-looking statements, we ask that
Viewers last night tuned into the nail-biting series finale of Line of Duty - which saw the mysterious antagonist H finally unmasked.
This morning, Britain s newspapers carried mixed reviews of the episode, with some pointing out gaping plot holes in the hugely-popular bent plot drama.
While some critics hailed the unveiling of H - revealed to be DSI Ian Buckells - as brilliantly tense , others called the finale something of a slow puncture .
Here, we round up what Britain s top TV pundits had to say.
Viewers last night tuned into the nail-biting series finale of Line of Duty (pictured) - which saw the mysterious antagonist H finally unmasked
This week s Bromsgrove and Droitwich Standard letters droitwichstandard.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from droitwichstandard.co.uk Daily Mail and Mail on Sunday newspapers.
PharmaTimes -
May 2021
This month we celebrate women from various factions of healthcare who are all striving to achieve better outcomes for patients in their vastly different roles, showcasing their careers, interests, achievements and thoughts on the future. Turn to page 17 to meet some of the brightest stars across pharma, communications and healthcare.
With patient outcomes also clearly centre stage, on page 30 Craig Adkins says now is the time to level up care for patients with irritable bowel disorder (IBD), a condition for which there is an urgent need for a national disease strategy and the application of a standard of care across the country, while on page 34, looking at 15 years of biosimilars in Europe, Rebecca Guntern highlights that the opportunity to leverage biosimilars ‘as an obvious and sustainable way to increase patient access to medicines has never been closer’.